<DOC>
	<DOCNO>NCT00330863</DOCNO>
	<brief_summary>This study design find whether take antipsychotic medication every two week injection compare take daily oral medication help people schizophrenia maintain good control symptom .</brief_summary>
	<brief_title>Preventing Relapse Schizophrenia : Oral Antipsychotics Compared To Injectables : Evaluating Efficacy</brief_title>
	<detailed_description>As case many chronic illness , challenge people schizophrenia take multiple pill every day long-term basis . At time , miss discontinue anti-psychotic medication treat schizophrenia substantially increase risk relapse re-hospitalization . This study determine effective long-acting injectable risperidone compare oral antipsychotic medication help patient schizophrenia . Patients enroll study randomly assign receive either long-acting injectable risperidone receive oral `` atypical '' antipsychotic medication . The `` atypical '' antipsychotic include patient oral group : aripiprazole , olanzapine , quetiapine , risperidone , ziprasidone . Patients `` oral '' group receive whichever five `` atypical '' antipsychotic medication study doctor decide best . Patients `` oral '' group allow switch others five medication study doctor think best . Patients study evaluate begin study every two week 30 month ( 2 1/2 year ) . Each two-week visit take 20 minute . At visit , patient receive medication examine side effect medication , vital sign ( heart rate , blood pressure , weight , waist measurement ) measure , ask question attendance visit take medication . The visit occur every three month take one hour , instead 20 minute , include additional question , examination muscle stiffness abnormal body movement , interview member research team conduct use computer technology . In addition , blood urine sample may collect seven time throughout 30 month study treatment . Patients enroll study halfway point study , may receive full 30 month treatment , plan patient opportunity receive less 18 month treatment .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>All schizophrenia schizoaffective patient whose clinician consider longterm treatment `` atypical '' ( second generation ) antipsychotic medication Worsening illness ( schizophrenia ) within 12 month study entry define : hospitalization , increase level clinical care , and/or present clinical Global Impressions Severity rating moderate bad First episode patient define patient : never receive antipsychotic medication never hospitalize psychiatric illness ; , receive antipsychotic medication first time associate first diagnosis schizophrenia . Pregnant breastfeeding Patients unstable medical condition Patients previous history failure respond adequate trial clozapine Patients know allergy risperidone previous history failure respond adequate trial risperidone . However , patient know allergy failure respond medication ( aripiprazole , olanzapine , quetiapine ziprasidone ) receive medication randomize oral medication arm , exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Relapse</keyword>
	<keyword>Prevention</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Injectable Medication</keyword>
</DOC>